Savin Svetlana, Cvejic Dubravka, Isic Tijana, Paunovic Ivan, Tatic Svetislav, Havelka Marija
Institute for the Application of Nuclear Energy-INEP, University of Belgrade, Zemun-Belgrade, Serbia.
Hum Pathol. 2008 Nov;39(11):1656-63. doi: 10.1016/j.humpath.2008.04.006. Epub 2008 Jul 26.
Thyroperoxidase and galectin-3 have been reported as useful immunohistochemical markers of thyroid malignancy. In this study, we evaluated the relationship between immunohistochemical staining results for these markers and clinicopathologic features of patients with differentiated thyroid cancer. A total of 193 archival thyroid samples including 28 follicular adenomas, 18 follicular carcinomas, and 147 papillary carcinomas with 114 adjacent thyroid tissues were analyzed by immunohistochemistry. Thyroperoxidase was underexpressed (<50% stained thyrocytes), and galectin-3 was expressed (>5% stained thyrocytes) in most carcinomas. The sensitivity for diagnosis of differentiated thyroid carcinoma was 86.1% for thyroperoxidase and 82.4% for galectin-3, whereas the combination of both markers increased the sensitivity up to 94.5%. Thus, the combination of thyroperoxidase and galectin-3 immunohistochemistry may help to ascertain the malignant nature of the lesion. Furthermore, tumor size, nodal involvement, extrathyroidal invasion, and high tumor-node-metastasis stage in patients with papillary carcinoma were related to thyroperoxidase absence and high galectin-3 expression in most cases (P < .05). In patients with follicular carcinoma, the extent of invasiveness was associated with galectin-3 positivity. Thus, expression of these markers is related to more or less aggressive biological behavior of differentiated thyroid carcinomas. Although thyroperoxidase presence may indicate favorable prognosis of papillary cancer, expression of galectin-3 illustrates the potential importance of this protein in the pathogenesis and/or progression of differentiated thyroid carcinomas.
甲状腺过氧化物酶和半乳糖凝集素-3已被报道为甲状腺恶性肿瘤有用的免疫组化标志物。在本研究中，我们评估了这些标志物的免疫组化染色结果与分化型甲状腺癌患者临床病理特征之间的关系。通过免疫组化分析了总共193份存档甲状腺样本，包括28例滤泡性腺瘤、18例滤泡性癌和147例乳头状癌以及114份相邻甲状腺组织。在大多数癌中，甲状腺过氧化物酶表达不足（<50%甲状腺细胞染色），而半乳糖凝集素-3表达（>5%甲状腺细胞染色）。甲状腺过氧化物酶诊断分化型甲状腺癌的敏感性为86.1%，半乳糖凝集素-3为82.4%，而两种标志物联合使用可将敏感性提高至94.5%。因此，甲状腺过氧化物酶和半乳糖凝集素-3免疫组化联合使用可能有助于确定病变的恶性性质。此外，在大多数情况下，乳头状癌患者的肿瘤大小、淋巴结受累、甲状腺外侵犯和高肿瘤-淋巴结-转移分期与甲状腺过氧化物酶缺失和半乳糖凝集素-3高表达相关（P<0.05）。在滤泡性癌患者中，侵袭程度与半乳糖凝集素-3阳性相关。因此，这些标志物的表达与分化型甲状腺癌或多或少的侵袭性生物学行为相关。虽然甲状腺过氧化物酶的存在可能表明乳头状癌预后良好，但半乳糖凝集素-3的表达说明了该蛋白在分化型甲状腺癌发病机制和/或进展中的潜在重要性。
